Eventide Healthcare & Life Sciences Fund CLASS I SHARES (ETIHX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions- the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors- including common stock- options- preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.


1 month+8.04% 3 years+11.91%
3 months+14.51% 5 years+24.74%
1 year+58.52% Since inception+25.98%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+24.74%+14.29%
Expense ratio1.35%1.29%
Risk 5 year sharpe ratio0.890.90
Net assets$639.8M$3.0B
Average market cap$2.4B$9.5B
Average P/E--21.7
Portfolio turnover27%27%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 5 Years
Minimal initial investment$100,000.00
Minimum IRA investment--


U.S. stock75.11%
International stock16.66%
Fixed income1.19%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
COLL Collegium Pharmaceutical Inc4.12%
ASND Ascendis Pharma A/S4.10%
SRPT Sarepta Therapeutics Inc3.13%
SAGE SAGE Therapeutics Inc2.92%
AIMT Aimmune Therapeutics Inc2.90%
-- 2.77%
BPMC Blueprint Medicines Corp2.57%
VRTX Vertex Pharmaceuticals Inc2.53%
VYGR Voyager Therapeutics Inc2.47%
NBIX Neurocrine Biosciences Inc2.42%